Citius Pharmaceuticals
CTXR
54 hedge funds and large institutions have $11.2M invested in Citius Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 10 closing their positions.
960% more call options, than puts
Call options by funds: $774K | Put options by funds: $73K
113% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 8
0.01% more ownership
Funds ownership: 0.38% → 0.39% (+0.01%)
4% less funds holding
Funds holding: 56 → 54 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
40% less capital invested
Capital invested by funds: $18.9M → $11.2M (-$7.62M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$390K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$312K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$300K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$217K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$55.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$2.28M |
| 2 |
E
Ergoteles
New York
|
-$460K |
| 3 |
Millennium Management
New York
|
-$255K |
| 4 |
SG Americas Securities
New York
|
-$108K |
| 5 |
HGWM
Horst & Graben Wealth Management
Portland,
Oregon
|
-$92K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PAG
51
Private Advisor Group
Morristown,
New Jersey
| $32 | – | – | – |
|
|
E
52
Ergoteles
New York
| – | -$460K | -15,203 | Closed |
|
|
53
SG Americas Securities
New York
| – | -$108K | -3,579 | Closed |
|
|
HGWM
54
Horst & Graben Wealth Management
Portland,
Oregon
| – | -$92K | -3,029 | Closed |
|
|
LP
55
LMR Partners
London,
United Kingdom
| – | -$71K | -2,357 | Closed |
|
|
GAM
56
Gotham Asset Management
New York
| – | -$2.28M | -879 | Closed |
|
|
TRCT
57
Tower Research Capital (TRC)
New York
| – | -$3.74K | -137 | -86% |
|
58
Barclays
London,
United Kingdom
| – | -$4K | -135 | Closed |
|
|
AIP
59
Almanack Investment Partners
Wayne,
Pennsylvania
| – | -$1K | -36 | Closed |
|
|
FSWA
60
Financial Synergies Wealth Advisors
Houston,
Texas
| – | -$242 | -8 | Closed |
|
|
TWC
61
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$121 | -3 | Closed |
|
CTXR Hedge Fund Activity: Q4 2022 in Review
54 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2022, worth a combined $11.2M — down 40% from $18.9M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CTXR and 9 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 17 added.
The largest buyer was GSA Capital Partners, adding an estimated $390K. The largest seller was Gotham Asset Management, exiting entirely with an estimated $2.28M sold.
- 54 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2022, down from 56 in Q3 2022.
- Funds reported $11.2M of Citius Pharmaceuticals stock for Q4 2022, down 40% quarter-over-quarter.
- 9 funds opened new Citius Pharmaceuticals positions in Q4 2022 and 10 closed out, a net change of -1 holder.
- The largest Citius Pharmaceuticals buyer in Q4 2022 was GSA Capital Partners, an estimated $390K added.
- The largest Citius Pharmaceuticals seller in Q4 2022 was Gotham Asset Management, an estimated $2.28M sold.
Based on aggregated 13F filings for Q4 2022.